The State of Peptides 2026

The global peptide therapeutics market is roughly $50–60 billion in 2026 by most analyst estimates. Grand View Research pegs it near $52B in 2024, with sustained compound annual growth in the 8–10% range through 2030. [verify against IQVIA / EvaluatePharma before press.] The variance between firms comes down to definitions — some include insulin (technically a peptide), some include vaccines. The order of magnitude is consistent: tens of billions globally, growing fast.

The market is, right now, mostly a GLP-1 market. The semaglutide franchise (Ozempic, Wegovy, Rybelsus) generated roughly $25B for Novo Nordisk and tirzepatide (Mounjaro, Zepbound) roughly $16B for Eli Lilly in the most recent full year. Those two drugs alone are ~$40B of the total — everything else is a smaller, more fragmented field around them.

The US is the dominant market (~60% of global therapeutic revenue), driven by both higher GLP-1 utilization and higher per-prescription pricing. Research and cosmetic peptides are growing faster in percentage terms off a much smaller base — and most research-peptide volume is gray-market and never appears in formal market sizing at all.

The Peptide Alliance directory is the proprietary spine of this report. As of July 2026 it contains 306 active verified suppliers (336 listings total) across six segments:

• Clinics — 121
• Peptide brands — 58
• Compounding pharmacies — 47
• Research labs — 38
• Manufacturers — 23
• Wholesale suppliers — 19

Geographic concentration is led by California, Florida, Texas, and Ontario, with meaningful density in New York and British Columbia. Coverage spans the US and Canada. Every count here is a live row in the directory.

One notable shift this cycle: the peptide-brands segment grew sharply, reflecting both new entrants and a deliberate expansion of coverage into research-vendor and next-gen-agonist brands.

The single biggest development of the past year is not inside the peptide industry at all — it is the realization, now priced by Wall Street, that appetite-suppressing drugs are large enough to destroy food demand at a national scale.

The numbers driving the thesis: roughly 1 in 8 US consumers now report using or having used a GLP-1; analysts estimate $30–55 billion in annual US food and beverage revenue is at risk by 2030; and the salty-snack category alone has been modeled to lose on the order of $12 billion. [verify each figure against the specific firm cited before press.]

Whether the exact numbers hold, the direction is no longer speculative — it is being disclosed on earnings calls and built into consumer-goods strategy. Peptides became a macro force the moment a diabetes-and-obesity drug started changing what a nation eats.

The most credible evidence is not the analyst decks — it is the operators saying it out loud:

• Walmart leadership publicly noted a measurable pull-back in basket size among GLP-1 users — the canonical "less food in the basket" moment that turned the thesis from theory into disclosed reality.
• PepsiCo and General Mills leadership have acknowledged smaller portions and shifting demand, and have begun reformulating and repackaging around it.

When the largest grocer and two of the largest food manufacturers on earth independently describe the same demand shift, it stops being a narrative and becomes a planning assumption.

The demand-destruction question is now a dedicated research line at essentially every major strategy and advisory firm:

• BCG, Bain (via the Consumer Goods Forum), McKinsey (grocery report), FTI Consulting, and KPMG all publish GLP-1 food-demand analyses.

For a peptide directory, this matters for one reason: it confirms that the peptide conversation has left the supplement forums and entered boardrooms and equity research. The audience for credible peptide information is now far larger than the people injecting it.

The ripple does not stop at "people eat less." The threads with real momentum:

• Protein and dairy demand surge. GLP-1 users are steered toward high-protein diets to preserve muscle, and demand has outrun supply in places — CNBC framed it bluntly as "dairy can't keep up."
• Smaller pack sizes. Manufacturers are reformatting around lower per-occasion consumption rather than just cutting volume.
• Downstream oddities. Even airlines have floated fuel-savings takes tied to lighter passengers — a sign of how far the second-order speculation now reaches.

The H2 edition will track which of these hold up and which fade.

Eli Lilly's triple agonist (GLP-1 + GIP + glucagon) is the most consequential pipeline drug since semaglutide. The TRIUMPH-1 Phase 2 trial produced ~24.2% mean body-weight reduction — the largest ever in this class. Phase 3 (TRIUMPH-3, -4, and -OSA) is enrolling, with a 2026 FDA filing guided and realistic approval in late 2026 to 2027.

New this cycle: data presented at the ADA conference reinforced retatrutide's profile, with strong weight-loss and blood-sugar results that keep it positioned as one of the most effective obesity/metabolic peptides in development. See the Retatrutide guide for the mechanism and the head-to-head comparison.

The implication is stark: a drug that meaningfully beats tirzepatide is coming, with no approved competitor in development. That expectation is already visible in the gray market — see the sourcing note in [The Regulatory Front](#) below.

Retatrutide is the front-runner, but a wave of dual and triple agonists is close behind:

• Cagrilintide / CagriSema — Novo Nordisk's long-acting amylin analog, paired with semaglutide, targeting greater weight loss via two satiety pathways.
• Survodutide — a GLP-1/glucagon dual agonist notable for reducing liver fat, advancing in MASH (fatty-liver disease).
• Mazdutide — a GLP-1/glucagon dual agonist moving quickly in China.

Each has its own database entry (cagrilintide, survodutide, mazdutide). The takeaway: the obesity market is about to go from two dominant drugs to a crowded, differentiated field — and the differentiation is increasingly about liver, muscle preservation, and dosing convenience, not just pounds lost.

A reclassification petition tied to current HHS leadership reached the FDA, and an advisory committee meeting is on the docket for July 2026 — now. Several widely used research peptides are expected to be discussed, including BPC-157, TB-500, MOTS-c, Semax, Epithalon, and DSIP.

We are not in the prediction business on the outcome. Our role is to set clean baselines now so the H2 edition can measure exactly what shifted — which compounds, if any, are reclassified, and what that does to legal availability and sourcing.

FDA scrutiny is increasing. Regulators continue targeting companies selling unapproved GLP-1s and research peptides, which is making compliance and sourcing a growing topic across the industry.

As of now, cost-effective research peptides remain widely available — but the risk that sourcing tightens in the near term is real, and buyers appear to know it. One field signal from a verified vendor: an uptick in bulk retatrutide orders, consistent with buyers stocking ahead of possible restriction. (See the verified-vendor note in [Supply & Trust](#).)

The practical guidance has not changed: source from verified, transparent vendors, keep documentation, and assume the compliance bar rises rather than falls.

The regulatory tightening is not only American. Australia and several other markets have announced increased efforts to regulate peptide imports and sales.

For a cross-border industry — where a large share of research-peptide supply moves internationally — this matters. Import enforcement, customs seizures, and domestic sales restrictions abroad can reshape which vendors can serve which markets, and how. The H2 edition will map the international enforcement picture in more detail.

The biggest structural shift of H1 was the closing of the compounded-GLP-1 window. Federal law (Sections 503A/503B) only permits mass compounding of FDA-approved drugs while they are on the shortage list. The FDA removed tirzepatide (late 2024) and semaglutide (Feb 2025) from that list, and the bulk pipeline that fueled the 2022–2024 weight-loss boom is gone. Compounded semaglutide volume is down an estimated ~90% year-over-year.

Individualized 503A prescriptions for documented medical need still exist, but the era of cheap, mass-compounded GLP-1s is over. Some of that demand migrated to branded supply — and some of it pushed back into the gray market, not out of it.

The industry's core structural problem got worse, not better: most buyers cannot tell a legitimate vendor from a junk one. Third-party testing is uneven, COA disclosure is uneven, and ad platforms (Meta, Google) still ban many of the most-searched terms — so reputable vendors cannot outbid the gray market on visibility.

Counterfeit semaglutide vials surfaced repeatedly, and the FDA issued multiple safety alerts. Communities like r/Peptidesource now spend real moderator effort surfacing reports of contaminated or off-spec product. The end of compounded GLP-1s poured more demand into exactly this trust vacuum.

The single most useful thing a buyer or clinician can do is refuse to source blind. In practice that means:

• Buy only from vendors that publish third-party COAs and disclose testing cadence.
• Prefer vendors with transparent contact details and a verifiable operation.
• Treat "cheapest at any cost" as the biggest red flag in a gray market.

This is the gap the Peptide Alliance directory was built to close — every listing is contacted, validated, and Trust-Scored. The forthcoming Vendor Transparency Index extends that into a public scoring framework (third-party testing, COA publication, contact transparency, compliance); it is previewed in this edition and launches, scored, in H2. If you take one action from this report, make it this: source only from verified suppliers.

Featured Partner — this is a sponsored listing, disclosed as such.

Hydro Research is a verified Featured Partner in the Peptide Alliance directory — a US research-peptide vendor emphasizing third-party purity verification and COA transparency, exactly the sourcing standard this chapter argues for.

• View their verified listing → Hydro Research on Peptide Alliance
• Visit their site → hydroresearchpeptides.com

The bulk-retatrutide-order signal noted in the Regulatory chapter is the kind of field data verified vendors like Hydro surface as the market moves.

Peptide revenue is made in a handful of distinct ways, each with a different margin and risk profile: branded pharma (Lilly, Novo — the GLP-1 giants); telehealth platforms (GLP-1 access at scale); compounding pharmacies (now compressed post-shortage); research-chem vendors (gray-market, high legal risk, no reliable public revenue data); clinics and med-spas (peptides as a high-margin add-on line); coaches and content/affiliate operators; and the new AI-native solo operator (see the case study below).

The center of gravity is shifting toward telehealth and clinics as the compounding lane narrows — and toward whoever can win trust and visibility in a market where advertising is restricted.

The defining business story of the cycle: Medvi, built by Matthew Gallagher, reportedly reached roughly $401M in first-year sales with about two human employees, running intake, triage, and customer operations largely on AI agents.

The lesson is not that everyone should copy it — the model has real cautionary notes, including reports of an AI chatbot hallucinating prices and product lines. The lesson is structural: the operational floor for a peptide-adjacent telehealth company has collapsed. A tiny team plus AI can now reach a scale that used to require hundreds of people. Expect more of these, and expect regulators to notice.

Roughly, from lowest to highest capital and risk:

• Affiliate / content — ~$0–500 to start; income is a function of audience.
• Research-chem reseller — low capital, high legal/regulatory risk.
• Practitioner adding peptides — moderate (protocols, compliance, sourcing).
• Med-spa / clinic peptide program — significant (licensed providers, compliance infrastructure; a full clinic buildout can run ~$400K+).
• Telehealth platform — highest complexity, though Medvi shows a leaner path by outsourcing the regulated components.

The money section is the most scrutinized part of any report that gets press, so every figure here should be traced to a credible source before publication.

The peptide conversation happens across five worlds — scientific/pharma R&D, clinical/practitioner, biohacking/longevity, fitness, and regulatory/compounding. We rank the events that matter in the companion Top Peptide Conferences page.

The short version: TIDES USA anchors the industry/BD side, the Peptide World Congress and A4M anchor the clinical side, and Dave Asprey's Beyond Biohacking plus the Health Optimisation Summit carry the consumer conversation. Where the compounded-GLP-1 fight is argued to lawmakers, it is at Compounders on Capitol Hill.

Grassroots peptide discussion lives on Reddit and adjacent forums — r/Peptides, r/Peptidesource, r/Biohackers, r/longevity — with a defining dynamic: platforms ban source and price discussion, so communities route off-platform to vetted source lists. That single dynamic is why a trusted directory matters so much.

Recurring themes: obsession with third-party testing and purity, fear of injections, evangelism versus skepticism, and a steady stream of "natural GLP-1 booster" sub-conversations. Grassroots sentiment is an early-warning system for what the broader market does next.

Serious coverage comes from STAT, Endpoints, and FiercePharma on the industry side, and increasingly from mainstream business media (CNBC, WSJ, NYT) on the GLP-1 macro story. The limits are real: ad-platform bans on certain compounds, differing FDA vs. Health Canada advertising rules, and a cautious mainstream posture leave a persistent coverage gap.

That gap — rigorous, plain-English peptide information that is neither hype nor hit-piece — is exactly what this report and the Peptide Alliance directory exist to fill.

Specific, checkable calls we will grade ourselves on next edition:

• The July FDA advisory produces movement on at least one of the named research peptides — clarity, not necessarily a ban.
• Retatrutide files with the FDA in 2026 and continues to lead the class on efficacy.
• The GLP-1 food-demand thesis shows up in more consumer-goods earnings commentary, not less.
• Sourcing tightens at the margins — more enforcement actions, more emphasis on verified vendors.
• The compounded-GLP-1 demand is shown to have split between branded supply and the gray market, not simply vanished.

The September/October H2 edition will report outcomes, not just baselines:

• The FDA advisory committee result and its effect on legal availability.
• The first hard numbers on where compounded-GLP-1 demand actually went.
• Retatrutide Phase 3 interim readouts where available.
• The Vendor Transparency Index — live and scored.
• Refreshed directory data, segment counts, and geographic distribution.

This is the value of a recurring report: H1 sets the baselines, H2 measures the movement. Come back for it.